Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ALPRAZOLAM STADAFARMA 0,5 MG COMPRIMIDOS EFG - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/ALPRAZOLAM STADAFARMA 0,5 MG COMPRIMIDOS EFG

Approved

STANDARD

ALPRAZOLAM STADAFARMA 0,5 MG COMPRIMIDOS EFG

Laboratorio Stada S.L.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Jan 25, 2024
Approval ID: 169bd84c4a6c2a46
Company: Laboratorio Stada S.L.
Type: Standard

Approval Details

Approval Id: 169bd84c4a6c2a46
Drug Cima Aemps Name: ALPRAZOLAM STADAFARMA 0,5 MG COMPRIMIDOS EFG
Register Number: 89268
Holder Company Name: Laboratorio Stada S.L.
Marketing Company Name: Laboratorio Stada S.L.
Authorization Date: 2024-01-25
Dosage Form: COMPRIMIDO
Dose: 0,5 mg
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica. Psicótropos
Commercialized: No
Company Name: Laboratorio Stada S.L.

Active Ingredients

ALPRAZOLAM

0,5 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Jan 25, 2024

Approval ID

169bd84c4a6c2a46

Type

Standard

Back to CIMA-AEMPS Approvals